| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 08.05.
| Dainippon Sumitomo Pharma gibt bekannt, dass Latuda® (Lurasidon HCl) primäre und wichtige sekundäre Endpunkte in zwei Phase-III-Studien zu Bipolar-I-Depression erreicht hat | | 64 | Business Wire |
| Daten wurden auf der 165. Jahrestagung der American Psychiatric
Association
in Philadelphia (Pennsylvania/USA) vorgelegt
Dainippon Sumitomo Pharma...
Mehr lesen zu:
Dainippon Sumitomo Pharma gibt bekannt, dass Latuda® (Lurasidon HCl) primäre und wichtige sekundäre Endpunkte in zwei Phase-III-Studien zu Bipolar-I-Depression erreicht hat | |
| 07.05.
| Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression | | 29 | Business Wire |
| Data Presented at the 165th Annual Meeting
of the American Psychiatric Association
in Philadelphia,
Pennsylvania
Dainippon Sumitomo Pharma...
Mehr lesen zu:
Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression | |
| 28.03.
| XFRA DIVIDEND INFORMATION - 28.03.2012 - 10 | | 58 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 28.03.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 28.03.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
TKY XFRA JP3571400005...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 28.03.2012 - 10 | |
| 27.03.
| XFRA DIVIDEND INFORMATION - 28.03.2012 - 9 | | 44 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 27.03.2012 CUM DIVIDENDE UND AM 28.03.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 27.03.2012. THE
EX-DIVIDEND DAY WILL BE 28.03.2012.
...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 28.03.2012 - 9 | |
| 02.03.
| Mintz Levin's Life Sciences Practice Represents Boston Biomedical, Inc. in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion | | 131 | Business Wire |
| The Life Sciences Practice of Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client,
Boston Biomedical, Inc. (BBI), in the company's definitive agreement...
Mehr lesen zu:
Mintz Levin's Life Sciences Practice Represents Boston Biomedical, Inc. in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion | |
| 01.03.
| Dainippon Sumitomo Pharma Co., Ltd. übernimmt Boston Biomedical, Inc. für bis zu 2,63 Mrd. US-Dollar; Übernahme beinhaltet eine weltweit führende Produkt-Pipeline zur Bekämpfung von Krebsstammzellen | | 46 | Business Wire |
|
Boston Biomedical, Inc. (BBI) hat heute den Abschluss einer endgültigen
Vereinbarung bekannt gegeben, nach der Dainippon Sumitomo Pharma Co.,
Ltd. (DSP) das Unternehmen...
Mehr lesen zu:
Dainippon Sumitomo Pharma Co., Ltd. übernimmt Boston Biomedical, Inc. für bis zu 2,63 Mrd. US-Dollar; Übernahme beinhaltet eine weltweit führende Produkt-Pipeline zur Bekämpfung von Krebsstammzellen | |
| 01.03.
| CORRECTING and REPLACING Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion; Acquisition includes a world-leading pipeline targeting cancer stem cells | | 46 | Business Wire |
| Please replace the release with the following corrected version due to
multiple revisions.
The corrected release reads:
DAINIPPON SUMITOMO...
Mehr lesen zu:
CORRECTING and REPLACING Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion; Acquisition includes a world-leading pipeline targeting cancer stem cells | |
| 01.03.
| Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion | | 43 | Business Wire |
| Acquisition includes a world-leading pipeline targeting cancer stem
cells
Boston Biomedical, Inc. (BBI) announced today that it has entered into a
...
Mehr lesen zu:
Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion | |
| 29.02.
| Dainippon Sumitomo Pharma to buy U.S. bio-venture | | - | Reuters.com |
| 15.12.
| CORRECTING and REPLACING In 2020, Forest/AstraZeneca/Dainippon Sumitomo's Teflaro and Trius Therapeutics' Tedizolid Will Capture Nearly One-Third of the MRSA Drug Market | | 100 | Business Wire |
| The Overall Hospital-Treated MRSA Infections Drug Market Will
Increase from $656 Million in 2010 to $730 Million in 2020, According to
Findings from Decision Resources
...
Mehr lesen zu:
CORRECTING and REPLACING In 2020, Forest/AstraZeneca/Dainippon Sumitomo's Teflaro and Trius Therapeutics' Tedizolid Will Capture Nearly One-Third of the MRSA Drug Market | |
| 15.12.
| In 2020, Forest/AstraZeneca/Dainippon Sumitomo's Teflaro and Trius Therapeutics' Tedizolid Will Capture Nearly One-Third of the MRSA Drug Market | | 37 | Business Wire |
| The Overall Hospital-Treated MRSA Infections Drug Market Will
Increase from $656 Million in 2010 to $730 Million in 2020, According to
Findings from Decision Resources
...
Mehr lesen zu:
In 2020, Forest/AstraZeneca/Dainippon Sumitomo's Teflaro and Trius Therapeutics' Tedizolid Will Capture Nearly One-Third of the MRSA Drug Market | |
